SFX by Ex Libris Inc.

Title:	Platelet transfusion in neonatal alloimmune thrombocytopenia
Source:	Blood [0006-4971] Allen, David yr:2007

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kiefel, V. "Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT)." Blood 107.9 (2006): 3761-3.
description	2.	Kaplan, C. "Alloimmune thrombocytopenia of the fetus and the newborn." Blood Reviews 16.1 (2002): 69-72.
description	3.	Killie, M. "Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia." BJOG 114.5 (2007): 588-95.
description	4.	Bussel, James B B. "Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens." Transfusion 47.1 (2006): 6-7.
description	5.	Schuh, A. "Prevention of worsening of severe thrombocytopenia after red cell transfusions by the use of leucocyte-depleted blood." British journal of haematology 108.2 (2000): 455-7.
description	6.	Gyamfi, C. "Alloimmune thrombocytopenia." Clinical obstetrics and gynecology 48.4: 897-909.
description	7.	Berkowitz, Richard L L. "Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia." Obstetrics and gynecology 107.1: 91-96.
description	8.	Peterson, Julie A A. "Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia." Transfusion 45.9 (2005): 1487-95.
description	9.	Kroll, H. "Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens." Transfusion (2005): 353-8.
description	10.	Rothenberger, S. "Neonatal alloimmune thrombocytopenia." Therapeutic apheresis 6.1: 32-35.
description	11.	Ward, Mary J J. "Long-Term Effects of Fetal and Neonatal Alloimmune Thrombocytopenia and Its Antenatal Treatment on the Medical and Developmental Outcomes of Affected Children." American journal of perinatology 23.8 (2006): 487-492.
description	12.	Urbaniak, I. "Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a." Transfusion 45.12 (2006): 1945-56.
description	13.	Jolly, Matthew C C. "The management of fetal alloimmune thrombocytopenia." Prenatal diagnosis (2002): 96-98.
description	14.	Kjeldsen-Kragh, J. "Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health care programme?" Transfusion and apheresis science 38.3 (2008): 183-8.
description	15.	Ansari, Mohammed Javeed I J. "Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice." Clinical immunology 126.2 (2007): 140-7.
description	16.	Anderson, T. "Guidelines on the use of intravenous immune globulin for hematologic conditions." Transfusion medicine reviews 21.2 (2007): 9-56.
description	17.	Sen, A. "Comparative study of predeposit and bedside leucodepletion filters." Medical journal, Armed Forces India 66.2 (2010): 142-146.
description	18.	Rosenberg, N. "Post-transfusion purpura--when and why?" The Israel Medical Association journal 8.10 (2006): 709-10.
description	19.	Henderson, J W W. "The cost effectiveness of prenatal care." Health care financing review 15.4 (1994): 21-32.
description	20.	Thung, Stephen F F. "The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia." American journal of obstetrics and gynecology 193.3 (2005): 1094-9.